Lupus Trials News

The best and brightest are working toward finding better treatments and ultimately a cure for lupus. Read about how the most important influencers in the lupus community are effecting lupus research, along with other issues that matter most to you.

Lupus Research Alliance Congratulates Dr. Betty Diamond for Well-Deserved Recognition by AAI

May 20, 2019 The LRA applauds Betty Diamond, MD for being named a Distinguished Fellow by the American Association of Immunologists (AAI) at their 2019 annual meeting. A top expert in lupus and autoimmune disease, Dr. Diamond co-chairs a committee of our affiliate Lupus Therapeutics Lupus Clinical Investigators Network (LuCIN) that evaluates drugs to be […]

Celebrate Clinical Trials Day May 20!

May 20, 2019 It’s Clinical Trials Day when the Lupus Research Alliance recognizes all the people we support who advance clinical research – scientists who identify and develop potential ways to diagnose, monitor and treat lupus,  researchers who design and conduct the studies to test these methods, and the volunteers who take part in the […]

The Numbers Add Up to 20 Years of Extraordinary Progress

May 1, 2019 The Lupus Research Alliance is honored to serve the lupus community as the global leader in lupus research, both in the resources we deploy and the results we deliver.  Collectively we have invested more than $200 million in over 500 grants selected by a multi-level peer review process led by world-class luminaries […]

Gene Changes Key to Successful Pregnancy in Lupus

April 29, 2019 Pregnant women with lupus are more likely to suffer complications than those who don’t. Lupus Research Alliance Scientific Advisory Board members Dr. Virginia Pascual, Professor at Weill Cornell Medicine; and Dr. Jane Salmon, Collette Kean Research Professor  at Hospital for Special Surgery, and their colleagues asked if testing the blood, of pregnant […]

Test Available to Address Blood Clots in Lupus

April 24, 2019 The pharmaceutical company Exagen, Inc. announced study results showing that a component of their AVISE SLE Monitor test, the biomarker PC4d, can assess risk for thrombosis – a blood clot in the blood vessels. Study author Dr. Michelle Petri, Professor of Medicine at the Johns Hopkins University School of Medicine and Director […]

Severe Mental Illness in Lupus Patients is Rare, Treatable, and Usually Short-Lived

April 18, 2019 A large international study has probed the causes of lupus-related psychosis—a serious condition marked by delusions and hallucinations. Dr. John Hanly and his co-authors at research centers across several continents found that lupus psychosis (LP) is quite rare, affecting only 1.5 percent of people with lupus. They also observed that the condition […]

Updates in Lupus Clinical Research from the LUPUS 2019 Meeting

April 11, 2019 The Lupus Research Alliance is pleased to share the results from four clinical trials presented at LUPUS 2019.  These studies continue to push our way forward toward new and improved treatments to help the lupus community. There’s a Silver Lining in New Belimumab Results Jim Oates, MD, Medical University of South Carolina, […]

New Treatment Approaches Supported by LRA Were Highlighted at LUPUS 2019

April 11, 2019 The bacteria that cause urinary tract infections may trigger lupus flares, a former Alzheimer’s disease therapy has shown promising results in research models—these are just some of the findings presented by Lupus Research Alliance-funded scientists at the 13th International Congress on Systematic Lupus Erythematosus (LUPUS 2019), held in San Francisco. Here are […]

LRA Funding Helps Identify Uncontrolled Blood Pressure as Particular Risk in Lupus

New results partially funded by the Lupus Research Alliance found that people with systemic lupus erythematosus have almost double the risk for a dangerous condition, resistant hypertension (RHTN) than those without the disease. RHTN is defined as blood pressure that either remains high despite treatment with three anti-hypertensive medications or is controlled only with four […]

Patients with Lupus Nephritis-Related Kidney Disease Are Living Longer

March 28, 2019 A new study published this March in Arthritis & Rheumatology found that deaths among patients with end-stage renal disease (ESRD) due to lupus nephritis (LN) fell significantly — by 32% —over the past two decades. The study took into account deaths from all causes, including deaths from cardiovascular disease (CVD) and infection. […]

Study Finds Mycophenolate Mofetil Comparable to Standard Treatment for Pediatric Lupus Nephritis

March 19, 2019 A new study published in Lupus showed that mycophenolate mofetil (MMF) is comparable in effectiveness to the standard treatment intravenous cyclophosphamide (IVCYC) for lupus nephritis in pediatric patients. The study compared response to treatment, kidney damage, time needed to result in inactive lupus nephritis and disease flares. Of the 51 patients studied, […]

LRA-Supported Researchers Developed a Model to Predict Full-Blown Lupus Nephritis Down the Road

A new study funded by the Lupus Nephritis Trials Network with support from the Lupus Research Alliance has proposed a set of standardized measures that promise to improve the way clinical trials in lupus nephritis (LN) are structured and how clinical researchers report their results. The findings will also help researchers in their search for […]

Lupus Research Alliance and National Minority Quality Forum Release Recommendations to Advance New Lupus Treatments by Increasing Diversity in Clinical Trial Participation

NEW YORK, NY. March 14, 2019.  The Lupus Research Alliance (LRA) and the National Minority Quality Forum (NMQF) today released the insightful report, Addressing the Challenges of Clinical Research Participation Among Populations Disproportionately Impacted by Lupus. The report presents findings and actionable recommendations ranging in scope that can be implemented by any individual or group seeking […]

Lupus Therapeutics Partners with Takeda to Test Potential Treatment for Lupus

New York, NY– March 1.  The Lupus Research Alliance and its affiliate, Lupus Therapeutics announced a collaboration with Takeda Pharmaceutical Company Limited, to evaluate the investigational biologic TAK-079 as a potential new therapy for lupus in a Phase 1 trial (NCT03724916).  The national study will be conducted in 20 research centers throughout the country, many […]

Lupus Research Alliance Congratulates NIH on 5-Year AMP Success

February 28, 2019 NEW YORK, NY. As a co-sponsor of the National Institutes of Health (NIH) public-private Accelerating Medicines Partnership (AMP), the Lupus Research Alliance is proud to share the project’s five-year achievements reported in Nature Reviews Drug Discovery.  In the article, NIH Director Dr. Francis Collins points to new technology standards AMP created for […]

LRA-funded Research Backs New Lupus Nephritis Clinical Trial

February 28, 2019 The biotechnology company Equillium Inc. just announced plans for a Phase 1 study to test the investigational monoclonal antibody EQ001 as a potential treatment for lupus nephritis (LN) that has not responded to existing treatment. The basis for this study is in part due to work conducted by Dr. Chandra Mohan that […]

Bacteria in the Gut May be a Cause of Lupus and Flares: Shows Study Supported by Lupus Research Alliance

NEW YORK, NY. February 19. Pieces of bacteria that escape from the intestines may trigger lupus and associated disease flares in some patients, according to a new study partly funded by the Lupus Research Alliance. These findings may allow disease treatment with probiotics or diets that alter the mix of bacterial species in the intestines. […]

Stelara® and Olumiant® Considered Promising by Lupus Expert

February 19, 2019 In Healio Rheumatology, Dr. Gregg Silverman, professor of medicine and pathology at NYU School of Medicine, provided an overview of potential lupus therapies in development.  He highlighted ustekinumab (brand name Stelara®) and baricitinib (brand name Olumiant®) as two drugs that look particularly promising. “The phase 2 extra-renal trial of baricitinib looks good; […]

New Approach to Treating Lupus Nephritis

February 6, 2019 Scientists partly funded by the Lupus Research Alliance have found a potential new way to protect the kidneys in patients with lupus. A study led by Dr. Vicki Rubin Kelley of Brigham and Women’s Hospital in Boston, Massachusetts, suggests that blocking a molecule made by some cells in the kidney could reduce […]

Protein Osteopontin Indicator of Lupus Nephritis, Shows Clinical Trial

February 1, 2019 Raised levels of a protein osteopontin were shown to indicate lupus nephritis and higher disease activity, in a new study conducted at 33 centers by top lupus researchers worldwide. Published in The Journal of Rheumatology, the study looked at results from 344 lupus patients. At the beginning of the study (baseline), patients […]

Lupus Therapeutics Launches Peer Training Program to Help Patients Benefit from Clinical Trials

February 1, 2019 Today, Lupus Therapeutics, an affiliate of Lupus Research Alliance, is launching our Patient Advocates for Lupus Studies (PALS) program with a pilot study to determine its effectiveness in increasing awareness of and participation in lupus clinical trials, particularly among diverse populations.  The program will pair people with lupus interested in learning about […]

Lupus Research Alliance and Lupus Therapeutics Partner on New Phase 3 Trial Testing Potential Benefit of Ustekinumab (Stelara®) in Lupus

February 1, 2019 The Lupus Research Alliance announced that its affiliate Lupus Therapeutics is working with the pharmaceutical company, Janssen, to help conduct a Phase 3 trial to evaluate whether their drug ustekinumab (Stelara®) may offer benefit to people with lupus.  Called LOTUS, the international study is being conducted in over 200 sites, 20 of […]

Lupus Research Alliance Announces Translational Research Grants to Speed Development of New Treatments

NEW YORK, NY – January 10.  Can “borrowed” drugs for treating other diseases protect the skin in patients with lupus? Can researchers coax the body to weed out harmful immune cells that drive tissue destruction in lupus? Those are just two of the innovative approaches for lupus therapies recognized by the Lupus Research Alliance with […]

Poor Dental Care Associated with Lupus

January 4, 2019 A study just published in Clinical and Experimental Rheumatology found that exposure to periodontal bacteria on the gums around the teeth can increase lupus disease activity.  The team of researchers at Oklahoma Medical Research Foundation examined blood samples from lupus patients to measure the amount of antibodies formed against specific bacteria.  They […]

Association Between Lupus and Cancer

January 4, 2019 A new analysis published in Arthritis Research & Therapy found that SLE is associated with increased risk of 16 cancers and decreased risk for prostate cancer and cutaneous (skin) melanoma.  The analysis included data from 24 published studies.  Increased risk was seen in non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, leukemia, multiple myeloma, cervix, vagina/vulva, renal, […]

End of content

No more pages to load